{"id":"comparator-sulfonylurea","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Weight gain"},{"rate":"1-3","effect":"Gastrointestinal disturbances"},{"rate":"1-2","effect":"Headache"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Comparator: Sulfonylurea","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:17:17.107107+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:17:22.394909+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Comparator: Sulfonylurea","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:17:22.591966+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3983509/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:17:23.775422+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulfonylureas bind to and inhibit ATP-sensitive potassium channels on the surface of pancreatic beta cells, leading to cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels in patients with type 2 diabetes.","oneSentence":"Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:43.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:17:25.371105+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06716216","phase":"PHASE3","title":"A Study of BGM0504 in Participants with Type 2 Diabetes","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-11-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537},{"nctId":"NCT04572165","phase":"","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","status":"UNKNOWN","sponsor":"Novo Nordisk A/S","startDate":"2021-01-26","conditions":"Diabetes Mellitus, Type 2","enrollment":600000},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT02973477","phase":"PHASE4","title":"Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-01-12","conditions":"Type2 Diabetes, Cardiovascular Diseases","enrollment":45},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathies","enrollment":44},{"nctId":"NCT01991197","phase":"PHASE2","title":"Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2014-04","conditions":"Psoriasis, Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02925559","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2016-10","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01177384","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-25","conditions":"Type 2 Diabetes Mellitus","enrollment":380},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00094770","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1172},{"nctId":"NCT02106104","phase":"PHASE4","title":"Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-03","conditions":"Type 2 Diabetes","enrollment":48},{"nctId":"NCT01658501","phase":"PHASE2","title":"Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM","status":"COMPLETED","sponsor":"PhaseBio Pharmaceuticals Inc.","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":593},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00082381","phase":"PHASE3","title":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Diabetes Mellitus, Type 2","enrollment":551},{"nctId":"NCT01137812","phase":"PHASE3","title":"The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":756},{"nctId":"NCT01156597","phase":"PHASE3","title":"Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00734591","phase":"","title":"Follow-Up Study for Exubera","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Diabetes Mellitus","enrollment":7439},{"nctId":"NCT00521742","phase":"PHASE3","title":"Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-03","conditions":"Diabetes Mellitus","enrollment":300},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00521820","phase":"PHASE3","title":"Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure","status":"TERMINATED","sponsor":"Takeda","startDate":"2000-06","conditions":"Diabetes Mellitus","enrollment":518},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367},{"nctId":"NCT00865436","phase":"PHASE1","title":"A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT00864734","phase":"PHASE1","title":"A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2002-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT00865241","phase":"PHASE1","title":"A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2002-11","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3983509"},"_approvalHistory":[],"publicationCount":2258,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comparator: Sulfonylurea","genericName":"Comparator: Sulfonylurea","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:17:25.371105+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}